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ficiency or reinfarction were present in 46.8% of patients. Mean homocysteine
levels in patients with and without early complications were 22.99±19.01 and
17.93±7.08 µmol/l, p=0.018. The unadjusted hazard ratio of homocysteine
level > 12µmol/l was 2.4, IC95% [1.04-5.65]. Cox proportional hazards model
showed that plasma homocysteine was not an independent correlate of inhos-
pital complications (Hazard ratio=1.43, IC95% [0.37-5.53], p=0.6). The mean
follow-up period after discharge was 17.2 months [12 – 28.8 months], 43.2%
of patients presented a late complication: death, cardiac insufficiency or myo-
cardial infarction. Homocysteine wasn't significantly correlated with late com-
plications (mean levels in patients with and without late complications:
18.67±5.99 and 20.19±13.07µmol/l, p=0.43). 
Conclusion: Homocysteine levels measured in the acute phase of STEMI
are correlated only with early but not late outcome and it isn’t an independent
predictor of inhospital major cardiovascular major complications. 
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Purpose: The objective of this study was to describe utilisation of newly
prescribed statins in French primary care.
Methods: From February 2008 to July 2009, 272 French general practitio-
ners (GPs) included 2122 patients treated with a new statin, out of which 670
were treated with rosuvastatin. For each patient, demographic characteristics,
comorbidities, concomitant drug and biological characteristics were docu-
mented.
Results: The mean patient age was 62.6 and there were slightly more men
(54.6%) than women. The main cardiovascular risk factors (RF) were: hyper-
tension (50.3%), diabetes (22.7%), family history of premature cardiovascular
disease (22.5%) and smoking (17.4%). Nearly 3 GPs out of 4 declared they
provide life-style and nutritional advice before initiating the treatment ; only
44.5% gave diet booklets. GPs are the main first-time statins prescribers
(88.9%) in France. This percentage was higher for rosuvastatin than for the
others statins (93.2% vs. 86.8% ; p<0.001). Two thirds of the patients received
a statin for the first time following the diagnosis of dyslipidemia. One third
was switched to a new statin. The reasons for the switch were related to lack
of effectiveness of previous treatment and to intolerance to previous statins
(mainly muscle weakness or pain). Before initiating treatment, biochemical
analysis was performed in 91% of patients. And 3 to 6 months after statin ini-
tiation, lipid levels, transaminase levels and CPK were measured in 67%, 40%
and 28% of all patients, respectively. At that time, 57.1% of patients reached
the LDL-cholesterol according to risk categories distribution. The proportion
of patients reaching the target was higher in the rosuvastatin group than in the
others statins group (62.3% vs .54.6% ; p=0.016). Overall, the achievement of
LDL-cholesterol targets was lower in patients with higher CV risk (Table).
Conclusions: In real-life conditions, LDL treatment targets are reached in
less than 2/3 of patients treated with statin. Achievement of LDL targets is less
frequent in patients at high cardiovascular risk leaving much room for
improvement.
Table – Achievement of therapeutic LDL targets
High Risk
N=520
≥3 RF
N=55
2 RF
N=204
1 RF
N=213
0 RF
N=118
Total
N=1110
LDL-cholesterol target <1g/l <1.3g/l <1.6g/l <1.9g/l <2.2g/l
Proportion achieving
LDL goals 33.3% 47.3% 69.6% 85.0% 94.9% 57.1%
